Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Panel: Telesta Bladder Cancer Drug Targeted Wrong Patients

This article was originally published in Scrip

Executive Summary

Telesta Therapeutics Inc.'s experimental drug Mycobacterium phlei cell wall-nucleic acid complex (MCNA) won't get its chance to potentially change the landscape of bladder cancer – or at least, not any time soon – if the FDA takes the advice of its advisory panel, which refused to back the marketing of the medicine for the indication the firm is seeking.


Related Content

Deal Watch: Ferring Enters New Therapeutic Area With Phase III Sciatica Candidate





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst